Use of Alflutop in complex treatment of patients with osteoarthritis

rheumatoid diseases, including osteoarthritis (OA), are serious and widespread disorders of the musculoskeletal system, characterized by damage to all joint structures, especially articular cartilage, subchondral bone, synovial membrane, as well as concomitant involvement of periarticular soft tissues in the inflammatory process, which significantly reduces the range of motion in the joints. According to WHO, over 170 million people worldwide suffer from OA. In developed countries, approximately 15% of the population is affected by this problem. In Russia, diseases of the musculoskeletal system, which include OA, rank third among causes of disability, second only to cardiovascular and oncological diseases, being one of the main causes of temporary loss of working capacity. The number of OA cases is growing year after year: if 2,769,901 cases were registered in 2016, then by 2019 the number had increased to 2,978,435. Recent studies show that the presence of OA increases the risk of mortality by 1.7 times [11]. Osteoarthritis is one of the causes of early loss of working capacity and disability. Previously, OA was considered part of the normal aging process; with age, the risk of the disease does increase, for example, among people over 50, the prevalence reaches 30%, and after 60 – up to 98%. However, modern studies confirm that OA is an independent disease, different from natural age-related changes in joints. Objective of the study: to evaluate the clinical efficacy of combination therapy with Alflutop and NSAIDs in comparison with NSAID monotherapy.

osteoarthritis, chondroprotectors, Alflutop, pharmacological effects, mechanism of action, combination therapy